Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22332287 | 0.85 | GNAI3 (0.43) | NPC1GNAI3GNAO1GNAI1HSD11B1 | |
| SCHEMBL22874701 | 0.83 | HSD11B1 (0.54) | NPC1GNAI3GNAO1GNAI1HSD11B1 | |
| SCHEMBL19249296 | 0.83 | EPHX2 (0.42) | NPC1EPHX2 | |
| SCHEMBL22874747 | 0.82 | NPC1 (0.53) | NPC1EPHX2GNAI3GNAO1GNAI1 | |
| SCHEMBL17546273 | 0.81 | NPC1 (0.65) | NPC1EPHX2 | |
| SCHEMBL7919921 | 0.81 | NPC1 (0.48) | NPC1EPHX2GNAI3GNAO1GNAI1 | |
| SCHEMBL22874702 | 0.81 | HSD11B1 (0.59) | GNAI3GNAO1GNAI1HSD11B1 | |
| SCHEMBL22874700 | 0.81 | HSD11B1 (0.63) | GNAI3GNAO1GNAI1HSD11B1 | |
| SCHEMBL22874752 | 0.80 | NPC1 (0.44) | NPC1GNAI3GNAO1GNAI1 | |
| SCHEMBL14147220 | 0.80 | NPC1 (0.47) | NPC1GNAI3GNAO1GNAI1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20200039960-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2020-02-06 | — | — | US | disclosed |
| EP-3428160-A1 | HETEROBICYCLOARYL RORC2 INHIBITORS AND METHODS OF USE THEREOF | Pfizer Inc (US) | 2019-01-16 | — | — | EP | disclosed |
| US-20180086736-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20160046597-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER (US) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039960-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | NPC1 253/4885EPHX2 994/4885GNAI3 346/4885 |
| US-20160046597-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | NPC1 253/4885EPHX2 994/4885GNAI3 346/4885 |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | CRBN, IKZF1, IKZF3 | NPC1 2155/4885EPHX2 4282/4885GNAI3 1551/4885 |
| US-20180086736-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | NPC1 253/4885EPHX2 994/4885GNAI3 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.